, Question 1
A patient on chronic high-dose aspirin is started on probenecid. Which
mechanism best explains the resulting decrease in uric acid excretion?
A. Probenecid inhibits renal tubular secretion of aspirin, increasing its
plasma concentration.
B. Aspirin competitively inhibits the URAT1 transporter, blocking
probenecid's uricosuric effect.
C. Probenecid induces CYP2C9, accelerating aspirin metabolism to
salicylate.
D. Aspirin displaces probenecid from plasma protein binding, reducing
its active free fraction.
Correct Answer: B - Aspirin competitively inhibits the URAT1
transporter, blocking probenecid's uricosuric effect.
RATIONALE
Low-dose aspirin inhibits URAT1-mediated urate reabsorption,
paradoxically reducing probenecid's uricosuric action by competing at
the tubular transporter. Probenecid does not significantly inhibit
aspirin secretion, and CYP2C9 induction or protein-binding
displacement are not the primary mechanisms.
Question 2
Which statement most accurately reflects the impact of a CYP2C19
loss-of-function allele on clopidogrel therapy after PCI?
A. It increases active metabolite formation, raising bleeding risk.
B. It reduces active metabolite formation, decreasing antiplatelet effect.
C. It has no effect because clopidogrel is activated by CYP3A4.
D. It enhances platelet inhibition via increased P2Y12 affinity.
Correct Answer: B - It reduces active metabolite formation,
decreasing antiplatelet effect.
Page 2
, RATIONALE
Clopidogrel is a prodrug requiring CYP2C19-mediated bioactivation;
loss-of-function alleles reduce active metabolite levels and antiplatelet
efficacy. CYP3A4 plays a minor role, and the allele does not increase
metabolite formation or P2Y12 affinity.
Question 3
Which pharmacodynamic principle explains why a partial agonist can act as a
functional antagonist in the presence of a full agonist?
A. It increases receptor affinity for the full agonist.
B. It occupies receptors but produces submaximal intrinsic activity,
reducing the full agonist's effect.
C. It enhances downstream signaling through allosteric modulation.
D. It upregulates receptor density, decreasing full agonist efficacy.
Correct Answer: B - It occupies receptors but produces
submaximal intrinsic activity, reducing the full agonist's effect.
RATIONALE
A partial agonist binds receptors with submaximal intrinsic activity;
when a full agonist is present, it competes for occupancy and reduces
the overall response, functioning as a functional antagonist. It does not
increase affinity, enhance signaling, or upregulate receptors.
Question 4
A patient on warfarin is prescribed fluconazole. Which interaction mechanism
best accounts for the resulting INR elevation?
A. Fluconazole induces CYP2C9, increasing warfarin metabolism.
B. Fluconazole inhibits CYP2C9, reducing warfarin clearance.
C. Fluconazole displaces warfarin from albumin, increasing free drug.
D. Fluconazole enhances vitamin K absorption, potentiating warfarin.
Correct Answer: B - Fluconazole inhibits CYP2C9, reducing
Page 3
, warfarin clearance.
RATIONALE
Fluconazole is a potent inhibitor of CYP2C9, which metabolizes
S-warfarin; inhibition reduces warfarin clearance and elevates INR.
Displacement from albumin is transient and not the primary
mechanism, and fluconazole does not induce CYP2C9 or enhance
vitamin K absorption.
Question 5
Which statement best describes the concept of 'pseudo-resistance' in
antimicrobial therapy?
A. Bacterial resistance due to enzymatic drug inactivation.
B. Clinical failure despite in vitro susceptibility due to poor drug
penetration or host factors.
C. Resistance caused by efflux pump overexpression.
D. Genetic mutation in the bacterial target site.
Correct Answer: B - Clinical failure despite in vitro susceptibility
due to poor drug penetration or host factors.
RATIONALE
Pseudo-resistance refers to clinical failure despite in vitro
susceptibility, often due to inadequate drug delivery (e.g., abscess,
poor perfusion) or host immune status. Enzymatic inactivation, efflux,
and target mutations are true resistance mechanisms.
Question 6
Which pharmacokinetic parameter is most directly affected by a drug's volume
of distribution (Vd) when calculating a loading dose?
A. Clearance
B. Bioavailability
C. Vd
Page 4
A patient on chronic high-dose aspirin is started on probenecid. Which
mechanism best explains the resulting decrease in uric acid excretion?
A. Probenecid inhibits renal tubular secretion of aspirin, increasing its
plasma concentration.
B. Aspirin competitively inhibits the URAT1 transporter, blocking
probenecid's uricosuric effect.
C. Probenecid induces CYP2C9, accelerating aspirin metabolism to
salicylate.
D. Aspirin displaces probenecid from plasma protein binding, reducing
its active free fraction.
Correct Answer: B - Aspirin competitively inhibits the URAT1
transporter, blocking probenecid's uricosuric effect.
RATIONALE
Low-dose aspirin inhibits URAT1-mediated urate reabsorption,
paradoxically reducing probenecid's uricosuric action by competing at
the tubular transporter. Probenecid does not significantly inhibit
aspirin secretion, and CYP2C9 induction or protein-binding
displacement are not the primary mechanisms.
Question 2
Which statement most accurately reflects the impact of a CYP2C19
loss-of-function allele on clopidogrel therapy after PCI?
A. It increases active metabolite formation, raising bleeding risk.
B. It reduces active metabolite formation, decreasing antiplatelet effect.
C. It has no effect because clopidogrel is activated by CYP3A4.
D. It enhances platelet inhibition via increased P2Y12 affinity.
Correct Answer: B - It reduces active metabolite formation,
decreasing antiplatelet effect.
Page 2
, RATIONALE
Clopidogrel is a prodrug requiring CYP2C19-mediated bioactivation;
loss-of-function alleles reduce active metabolite levels and antiplatelet
efficacy. CYP3A4 plays a minor role, and the allele does not increase
metabolite formation or P2Y12 affinity.
Question 3
Which pharmacodynamic principle explains why a partial agonist can act as a
functional antagonist in the presence of a full agonist?
A. It increases receptor affinity for the full agonist.
B. It occupies receptors but produces submaximal intrinsic activity,
reducing the full agonist's effect.
C. It enhances downstream signaling through allosteric modulation.
D. It upregulates receptor density, decreasing full agonist efficacy.
Correct Answer: B - It occupies receptors but produces
submaximal intrinsic activity, reducing the full agonist's effect.
RATIONALE
A partial agonist binds receptors with submaximal intrinsic activity;
when a full agonist is present, it competes for occupancy and reduces
the overall response, functioning as a functional antagonist. It does not
increase affinity, enhance signaling, or upregulate receptors.
Question 4
A patient on warfarin is prescribed fluconazole. Which interaction mechanism
best accounts for the resulting INR elevation?
A. Fluconazole induces CYP2C9, increasing warfarin metabolism.
B. Fluconazole inhibits CYP2C9, reducing warfarin clearance.
C. Fluconazole displaces warfarin from albumin, increasing free drug.
D. Fluconazole enhances vitamin K absorption, potentiating warfarin.
Correct Answer: B - Fluconazole inhibits CYP2C9, reducing
Page 3
, warfarin clearance.
RATIONALE
Fluconazole is a potent inhibitor of CYP2C9, which metabolizes
S-warfarin; inhibition reduces warfarin clearance and elevates INR.
Displacement from albumin is transient and not the primary
mechanism, and fluconazole does not induce CYP2C9 or enhance
vitamin K absorption.
Question 5
Which statement best describes the concept of 'pseudo-resistance' in
antimicrobial therapy?
A. Bacterial resistance due to enzymatic drug inactivation.
B. Clinical failure despite in vitro susceptibility due to poor drug
penetration or host factors.
C. Resistance caused by efflux pump overexpression.
D. Genetic mutation in the bacterial target site.
Correct Answer: B - Clinical failure despite in vitro susceptibility
due to poor drug penetration or host factors.
RATIONALE
Pseudo-resistance refers to clinical failure despite in vitro
susceptibility, often due to inadequate drug delivery (e.g., abscess,
poor perfusion) or host immune status. Enzymatic inactivation, efflux,
and target mutations are true resistance mechanisms.
Question 6
Which pharmacokinetic parameter is most directly affected by a drug's volume
of distribution (Vd) when calculating a loading dose?
A. Clearance
B. Bioavailability
C. Vd
Page 4
